Sernova Biotherapeutics (OTCMKTS:SEOVF – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports.
Sernova Biotherapeutics Price Performance
Shares of OTCMKTS SEOVF remained flat at $0.11 during midday trading on Thursday. The stock had a trading volume of 620 shares, compared to its average volume of 25,062. The company has a market cap of $41.54 million, a P/E ratio of -2.75 and a beta of 0.82. Sernova Biotherapeutics has a fifty-two week low of $0.09 and a fifty-two week high of $0.16. The business has a fifty day moving average of $0.12 and a two-hundred day moving average of $0.11.
Sernova Biotherapeutics Company Profile
Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.
In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation.
Read More
- Five stocks we like better than Sernova Biotherapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Sernova Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
